Key Insights

Highlights

Success Rate

63% trial completion

Published Results

13 trials with published results (45%)

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 62/100

Termination Rate

34.5%

10 terminated out of 29 trials

Success Rate

63.0%

-23.5% vs benchmark

Late-Stage Pipeline

7%

2 trials in Phase 3/4

Results Transparency

76%

13 of 17 completed with results

Key Signals

13 with results63% success

Data Visualizations

Phase Distribution

29Total
Not Applicable (3)
P 1 (6)
P 2 (18)
P 3 (2)

Trial Status

Completed17
Terminated10
Withdrawn1
Unknown1

Trial Success Rate

63.0%

Benchmark: 86.5%

Based on 17 completed trials

Clinical Trials (29)

Showing 20 of 20 trials
NCT01382706Phase 2Terminated

Docetaxel and Lapatinib in Metastatic Transitional Cell Carcinoma in Bladder

NCT03081858Phase 1Completed

Proliposomal Intravesical Paclitaxel for Treatment of Low-Grade, Stage Ta, Non Muscle Invasive Bladder Cancer

NCT02318329Phase 1Completed

Open-Label, Dose-Finding Study Evaluating Safety and PK of FPA144 in Patients With Advanced Solid Tumors

NCT05121948Phase 1Terminated

A Study of HC-7366 to Establish the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D)

NCT01954173Not ApplicableTerminated

Adjuvant Radiation for High Risk Bladder Cancer

NCT03263039Phase 2UnknownPrimary

Biomarkers in Urothelial Cancer Patients Treated With Pembrolizumab

NCT02897765Phase 1Completed

A Personal Cancer Vaccine (NEO-PV-01) w/ Nivolumab for Patients With Melanoma, Lung Cancer or Bladder Cancer

NCT00478361Phase 2Completed

Gemcitabine, Paclitaxel, Doxorubicin in Metastatic or Unresectable Bladder Cancer With Decreased Kidney Function

NCT01118351Phase 2Terminated

Sunitinib Malate in Treating Patients With Recurrent Transitional Cell Bladder Cancer

NCT00112671Phase 2Completed

Sorafenib in Treating Patients With Advanced or Metastatic Cancer of the Urinary Tract

NCT01108003Not ApplicableTerminated

Broccoli Sprout Extract in Treating Patients With Transitional Cell Bladder Cancer Undergoing Surgery

NCT01828736Phase 2Completed

Efficacy of Combination of Trastuzumab to Gemcitabine - Platinum Advanced or Metastatic Urothelial Carcinoma

NCT00028756Phase 3Completed

Comparison of Immediate and Delayed Adjuvant Chemotherapy in Treating Patients Who Have Undergone a Radical Cystectomy for Stage III or Stage IV Transitional Cell Carcinoma of the Bladder Urothelium

NCT00859339Phase 2TerminatedPrimary

Neoadjuvant Cisplatin, Gemcitabine, Sunitinib Malate + Radical Cystectomy for TCC

NCT02101931Phase 3CompletedPrimary

A Laser Detection for Bladder Cancer by (Photodynamic) Spectra of Urine

NCT00706641Not ApplicableCompletedPrimary

Neoadjuvant Dasatinib and Radical Cystectomy for Transitional Cell Carcinoma of the Bladder

NCT01824329Phase 2Completed

Prostate Capsule Sparing Cystectomy and Nerve-sparing Radical Cystoprostatectomy in Men With Bladder Cancer

NCT00363883Phase 2Terminated

Vorinostat in Treating Patients With Locally Recurrent or Metastatic Cancer of the Urothelium

NCT00407485Phase 2Completed

VEGF Trap in Treating Patients With Recurrent, Locally Advanced, or Metastatic Cancer of the Urothelium

NCT00471536Phase 2Completed

Pazopanib in Treating Patients With Metastatic Urothelial Cancer

Scroll to load more

Research Network

Activity Timeline